Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells

Jianchuan Xia, Yasuhiro Tanaka, Shigeo Koido, Chunlei Liu, Pinku Mukherjee, Sandra J Gendler, Jianlin Gong

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Genetically modified mice with spontaneous development of mammary carcinoma provide a powerful tool to study the efficacy of tumor vaccines, since they mimic breast cancer development in humans. We used a transgenic murine model expressing poly-omavirus middle T oncogene and mucin 1 tumor-associated Ag to determine the preventive effect of a dendritic/tumor fusion cell vaccine. The MMT (a transgenic murine model) mice developed mammary carcinoma between the ages of 65-108 days with 100% penetrance. No spontaneous CTL were detected. However, prophylactic vaccination of MMT mice with dendritic/tumor fusion cells induced polyclonal CTL activity against spontaneous mammary carcinoma cells and rendered 57-61% of the mice free of the disease at the end of experiment (180 days). Furthermore, the level of CTL activity was maintained with multiple vaccinations. The antitumor immunity induced by vaccination with dendritic/tumor fusion cells reacted differently to injected tumor cells and autochthonous tumor. Whereas the injected tumor cells were rejected, the autochthonous tumor evaded the attack and was allowed to grow. Collectively these results indicate that prophylactic vaccination with dendritic/tumor fusion cells confers sufficient antitumor immunity to counter the tumorigenesis of potent oncogenic products. The findings in the present study are highly relevant to cancers in humans.

Original languageEnglish (US)
Pages (from-to)1980-1986
Number of pages7
JournalJournal of Immunology
Volume170
Issue number4
StatePublished - Feb 15 2003

Fingerprint

Cell Fusion
Vaccination
Breast Neoplasms
Neoplasms
Immunity
Mucin-1
Cancer Vaccines
Penetrance
Human Development
Oncogenes
Carcinogenesis
Vaccines

ASJC Scopus subject areas

  • Immunology

Cite this

Xia, J., Tanaka, Y., Koido, S., Liu, C., Mukherjee, P., Gendler, S. J., & Gong, J. (2003). Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. Journal of Immunology, 170(4), 1980-1986.

Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. / Xia, Jianchuan; Tanaka, Yasuhiro; Koido, Shigeo; Liu, Chunlei; Mukherjee, Pinku; Gendler, Sandra J; Gong, Jianlin.

In: Journal of Immunology, Vol. 170, No. 4, 15.02.2003, p. 1980-1986.

Research output: Contribution to journalArticle

Xia, J, Tanaka, Y, Koido, S, Liu, C, Mukherjee, P, Gendler, SJ & Gong, J 2003, 'Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells', Journal of Immunology, vol. 170, no. 4, pp. 1980-1986.
Xia, Jianchuan ; Tanaka, Yasuhiro ; Koido, Shigeo ; Liu, Chunlei ; Mukherjee, Pinku ; Gendler, Sandra J ; Gong, Jianlin. / Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. In: Journal of Immunology. 2003 ; Vol. 170, No. 4. pp. 1980-1986.
@article{5da9f8c73d3c4b04afe0df0ce634b16f,
title = "Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells",
abstract = "Genetically modified mice with spontaneous development of mammary carcinoma provide a powerful tool to study the efficacy of tumor vaccines, since they mimic breast cancer development in humans. We used a transgenic murine model expressing poly-omavirus middle T oncogene and mucin 1 tumor-associated Ag to determine the preventive effect of a dendritic/tumor fusion cell vaccine. The MMT (a transgenic murine model) mice developed mammary carcinoma between the ages of 65-108 days with 100{\%} penetrance. No spontaneous CTL were detected. However, prophylactic vaccination of MMT mice with dendritic/tumor fusion cells induced polyclonal CTL activity against spontaneous mammary carcinoma cells and rendered 57-61{\%} of the mice free of the disease at the end of experiment (180 days). Furthermore, the level of CTL activity was maintained with multiple vaccinations. The antitumor immunity induced by vaccination with dendritic/tumor fusion cells reacted differently to injected tumor cells and autochthonous tumor. Whereas the injected tumor cells were rejected, the autochthonous tumor evaded the attack and was allowed to grow. Collectively these results indicate that prophylactic vaccination with dendritic/tumor fusion cells confers sufficient antitumor immunity to counter the tumorigenesis of potent oncogenic products. The findings in the present study are highly relevant to cancers in humans.",
author = "Jianchuan Xia and Yasuhiro Tanaka and Shigeo Koido and Chunlei Liu and Pinku Mukherjee and Gendler, {Sandra J} and Jianlin Gong",
year = "2003",
month = "2",
day = "15",
language = "English (US)",
volume = "170",
pages = "1980--1986",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells

AU - Xia, Jianchuan

AU - Tanaka, Yasuhiro

AU - Koido, Shigeo

AU - Liu, Chunlei

AU - Mukherjee, Pinku

AU - Gendler, Sandra J

AU - Gong, Jianlin

PY - 2003/2/15

Y1 - 2003/2/15

N2 - Genetically modified mice with spontaneous development of mammary carcinoma provide a powerful tool to study the efficacy of tumor vaccines, since they mimic breast cancer development in humans. We used a transgenic murine model expressing poly-omavirus middle T oncogene and mucin 1 tumor-associated Ag to determine the preventive effect of a dendritic/tumor fusion cell vaccine. The MMT (a transgenic murine model) mice developed mammary carcinoma between the ages of 65-108 days with 100% penetrance. No spontaneous CTL were detected. However, prophylactic vaccination of MMT mice with dendritic/tumor fusion cells induced polyclonal CTL activity against spontaneous mammary carcinoma cells and rendered 57-61% of the mice free of the disease at the end of experiment (180 days). Furthermore, the level of CTL activity was maintained with multiple vaccinations. The antitumor immunity induced by vaccination with dendritic/tumor fusion cells reacted differently to injected tumor cells and autochthonous tumor. Whereas the injected tumor cells were rejected, the autochthonous tumor evaded the attack and was allowed to grow. Collectively these results indicate that prophylactic vaccination with dendritic/tumor fusion cells confers sufficient antitumor immunity to counter the tumorigenesis of potent oncogenic products. The findings in the present study are highly relevant to cancers in humans.

AB - Genetically modified mice with spontaneous development of mammary carcinoma provide a powerful tool to study the efficacy of tumor vaccines, since they mimic breast cancer development in humans. We used a transgenic murine model expressing poly-omavirus middle T oncogene and mucin 1 tumor-associated Ag to determine the preventive effect of a dendritic/tumor fusion cell vaccine. The MMT (a transgenic murine model) mice developed mammary carcinoma between the ages of 65-108 days with 100% penetrance. No spontaneous CTL were detected. However, prophylactic vaccination of MMT mice with dendritic/tumor fusion cells induced polyclonal CTL activity against spontaneous mammary carcinoma cells and rendered 57-61% of the mice free of the disease at the end of experiment (180 days). Furthermore, the level of CTL activity was maintained with multiple vaccinations. The antitumor immunity induced by vaccination with dendritic/tumor fusion cells reacted differently to injected tumor cells and autochthonous tumor. Whereas the injected tumor cells were rejected, the autochthonous tumor evaded the attack and was allowed to grow. Collectively these results indicate that prophylactic vaccination with dendritic/tumor fusion cells confers sufficient antitumor immunity to counter the tumorigenesis of potent oncogenic products. The findings in the present study are highly relevant to cancers in humans.

UR - http://www.scopus.com/inward/record.url?scp=0037442132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037442132&partnerID=8YFLogxK

M3 - Article

VL - 170

SP - 1980

EP - 1986

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -